Dutch Bros cleared its Q1 earnings hurdle last week — and options traders are now leaning more bullish than at any point in the past year.
The sharpest signal this week sits in options. Call demand has surged relative to puts: the put/call ratio has collapsed to 0.54, nearly 2.5 standard deviations below its 20-day average of 0.63. That makes this the most call-skewed reading of the past 52 weeks, where the full-year low is 0.37 and the high is 1.04. This is a decisive shift from the pre-earnings posture. A fortnight ago, the PCR was running close to its average at 0.63. The +10.6% company-operated same-store sales beat — combined with raised full-year guidance — appears to have redirected options flow toward upside exposure.
Short positioning tells a story of bears retreating after the print. Short interest peaked above 21.7 million shares around May 8, then dropped sharply in the days following the May 7 earnings release, falling roughly 14% over the week. It now stands at 14.6% of the free float — still elevated by any standard, but meaningfully lower than the near-16% level that built up through late April. The borrow market is not signalling stress: the cost to borrow has eased to just 0.44% annually, down 14% on the week, and availability is running at 188% of current short interest — comfortably within normal range and well above the 52-week tightest level of 138%. Shorts can build or exit positions without fighting the lending market.
The Street lined up constructively after the print. Most post-earnings analyst actions kept or raised targets, with Citigroup lifting to $85 and KeyBanc moving to $79, both maintaining positive ratings. Barclays trimmed fractionally from $76 to $75 but held its Overweight. TD Cowen reiterated a Buy at $73 this morning. The consensus is firmly Buy, with a mean price target of $76.58 against a current price of $52.77 — implying roughly 45% return potential. The bull case centres on the SSS acceleration and unit growth trajectory. The bear case acknowledges competitive pressure from McDonald's energy drink push, while conceding that similar category entrants have historically broadened demand rather than cannibalised it. EPS momentum is the standout factor score at 87th percentile on a 30-day basis and 81st on 90 days — the earnings beat is registering clearly in forward estimate revisions.
Institutional ownership shifts add texture to the recovery narrative. BlackRock added 6.6 million shares in the latest reported period, pushing its stake to 10.1% of shares. FMR (Fidelity) added 4.1 million, reaching 9.9%. T. Rowe Price disclosed an even larger build of 7.5 million shares through March. These are material additions from three of the largest institutional holders. The pattern suggests funds were accumulating during the late-2025 and early-2026 weakness — a period when the stock gave up significant ground — rather than chasing the recovery. Co-founder Travis Boersma holds roughly 7.2% of shares with a near-9.9 million share position reported as of April 27. On the insider front, director Todd Penegor made an open-market purchase of 2,000 shares at $51.18 on May 15 — a small transaction but notable as a cash buy in the days following the earnings release.
The stock added 4.1% on the week to close at $52.77, while close peers had a more mixed session. SHAK surged 7.4% on Tuesday alone but is down 2.9% on the week. CMG and CAVA each posted modest weekly gains of roughly 1.1–1.2%, while DNUT slipped 2.1%. Dutch Bros' relative outperformance is consistent with post-earnings short covering and fresh buying, rather than broad sector momentum.
What to watch next: the next earnings release is scheduled for August 6, giving the stock nearly twelve weeks to trade on the raised guidance — the degree to which the SSS trend holds through Q2 checks and whether the current short interest of 14.6% continues to unwind or rebuilds will define how much of that analyst target gap actually closes.
See the live data behind this article on ORTEX.
Open BROS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
